

Human B7-H3 Monoclonal Antibody

Catalog No.: YR0156

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

What is ifinatamab biosimilar research grade? Ifinatamab is a humanized IgG1-kappa monoclonal antibody against the human B7-H3 (CD276) protein, a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal (healthy) tissues. It was reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers. Ifinatamab biosimilar uses the same protein sequences as the therapeutic antibody ifinatamab.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Ifinatamab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Human B7-H3

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)